Wasatch Photonics recalled 192 Raman spectrometers on August 4, 2025. Two potential laser safety failure modes could pose serious risks. No incidents have been reported, but excessive force or vibration may trigger failures.
Two new potential laser safety failure modes have been identified in the product design. Overcurrent of laser diode, and a fail-unsafe mode. The failure modes have never been found to occur in these models, whether in the field or factory, but could potentially occur under excessive force or extreme, continuous vibration.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact WASATCH PHOTONICS or your healthcare provider for instructions. Notification method: N/A
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recall involves Wasatch Photonics 785/830-SR and 785-ER-ILC Raman Spectrometers. Affected models include 785-SR-ILP, 785-SR-ILC, 830-SR-ILP, 830-SR-ILC, and 785-ER-ILC. These devices were distributed in the U.S.
The recall addresses two potential laser safety failure modes. These include overcurrent of the laser diode and a fail-unsafe mode that could occur under excessive force or extreme vibration.
No incidents or injuries have been reported related to these models. The manufacturer has not found these failure modes occurring in the field or factory.
Stop using the devices immediately. Follow the recall instructions provided by the manufacturer and contact Wasatch Photonics or your healthcare provider for further guidance.
For more information, contact Wasatch Photonics at their official website or through their customer service hotline. Visit https://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?recall_number=Z-2478-2025 for details.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.